Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares (2022 - 2025)

Ocular Therapeutix (OCUL) has 5 years of Treasury Shares data on record, last reported at $4.4 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 28.61% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, up 28.61%, while the annual FY2025 figure was $4.4 million, 28.61% up from the prior year.
  • Treasury Shares reached $4.4 million in Q4 2025 per OCUL's latest filing, up from $3.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.4 million in Q4 2025 and bottomed at $1.1 million in Q4 2022.
  • Average Treasury Shares over 4 years is $2.6 million, with a median of $2.5 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: surged 108.29% in 2024, then grew 28.61% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $1.1 million in 2022, then soared by 48.93% to $1.6 million in 2023, then soared by 108.29% to $3.4 million in 2024, then increased by 28.61% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $4.4 million in Q4 2025, $3.4 million in Q4 2024, and $1.6 million in Q4 2023.